Folkehelseinstituttet
Not a member yet
10872 research outputs found
Sort by
Is smokeless tobacco a healthier option in patients with AUD? A follow-up study during treatment
Get PDFpublishedVersio
The association between lumbar lordosis preoperatively and changes in PROMs for lumbar spinal stenosis patients 2 years after spinal surgery: radiological and clinical results from the NORDSTEN-spinal stenosis trial
Get PDFBackground Patients with lumbar spinal stenosis (LSS) sometimes have lower lumbar lordosis (LL), and the incidence of LSS correlates closely with the loss of LL. The few studies that have evaluated the association between LL and clinical outcomes after non-instrumented surgery for LSS show conflicting results. This study investigates the association between preoperative LL and changes in PROMs 2 years after decompressive surgery. Method This prospective cohort study obtained preoperative and postoperative data for 401 patients from the multicenter randomized controlled spinal stenosis trial as part of the NORwegian degenerative spondylolisthesis and spinal STENosis (NORDSTEN) study. Before surgery, the radiological sagittal alignment parameter LL was measured using standing X-rays. The association between LL and 2-year postoperative changes was analyzed using the oswestry disability index (ODI), a numeric rating scale (NRS) for low back and leg pain, the Zurich claudication questionnaire (ZCQ), and the global perceived effect (GPE) score. The changes in PROMs 2 years after surgery for quintiles of lumbar lordosis were adjusted for the respective baseline PROMs: age, sex, smoking, and BMI. The Schizas index and the Pfirrmann index were used to analyze multiple regressions for changes in PROMs. Results There were no associations in the adjusted and unadjusted analyses between preoperative LL and changes in ODI, ZCQ, GPE, and NRS for back and leg pain 2 years after surgery. Conclusion LL before surgery was not associated with changes in PROMs 2 years after surgery. Lumbar lordosis should not be a factor when considering decompressive surgery for LSS.publishedVersio
Acceptability, values, and preferences of older people for chronic low back pain management; a qualitative evidence synthesis
Get PDFpublishedVersio
Safety of Tiger nuts (Cyperus esculentus) oil as a novel food pursuant to Regulation (EU) 2015/2283
Get PDFpublishedVersio
BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway
Get PDFObjective This study aimed to explore the frequency of BRCA mutations and testing, age at diagnosis, and incidence of ovarian cancer and to describe oncologic outcomes in patients carrying BRCA mutation compared with those not carrying mutation, in 1 cancer center that covers two-thirds of the Norwegian population. Methods Patients with ovarian cancer treated at Oslo University Hospital-Radiumhospital 2008-2019 who accepted BRCA testing were prospectively registered in the study. Patients carrying mutation and their families received genetic counseling and risk-reducing surgery. For patients treated from 2014 to 2019 (N = 1032), detailed clinicopathologic data (International Federation of Gynecology and Obstetrics stage, histopathology, type of surgery, residual disease, chemotherapy, first recurrence, and survival) were obtained. Overall and progression-free survival were analyzed using Kaplan-Meier curves and Cox regressions. Linear trends were assessed using linear regressions. Using data delivered by the Cancer Registry of Norway, we assessed ovarian cancer incidence in the uptake area of Oslo University Hospital-Radiumhospital throughout the study period. Results A total of 1579 patients were registered. Throughout the study period, BRCA mutation frequency was decreasing, from 14.5% to 6.8%, and mean age at diagnosis increasing, from 59.4 to 63.8 years, in 2008 and 2019, respectively. Patients carrying BRCA1 mutation were younger at diagnosis than were patients carrying BRCA2 mutation and those not carrying mutation. Patients carrying BRCA mutation had almost exclusively high-grade serous histology, and had more often advanced disease and higher cancer antigen 125 levels at the time of diagnosis and were more often treated with interval debulking surgery than were those not carrying mutation. Patients carrying BRCA2 mutation had better overall survival than did those not carrying mutation. The incidence rate of ovarian cancer was decreasing throughout the study, from 22 to 18 per 100,000 person-years in 2008 and 2019, respectively. Conclusion BRCA mutation testing in patients with ovarian cancer has become more widely incorporated into clinical practice over time, owing to its importance for prognosis and for risk-reducing measures in the families of patients carrying mutation, and possibly contributes to a decrease in ovarian cancer incidence.BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in NorwaypublishedVersio
Bariatric surgery patients in AUD treatment in Norway—an exploratory cross-sectional study
Get PDFpublishedVersio
Susceptibility and infectiousness of SARS-CoV-2 in children versus adults, by variant (wild-type, alpha, delta): A systematic review and meta-analysis of household contact studies
Get PDFpublishedVersio
